feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / New TB Vaccine Promises Hope Against Deadly Disease

New TB Vaccine Promises Hope Against Deadly Disease

25 Nov, 2025

•

Summary

  • A new HSP Subunit Vaccine is nearing commercial availability.
  • Existing vaccines are largely ineffective for adult TB prevention.
  • IIT Bhubaneswar and ILS Bhubaneswar developed the novel vaccine.
New TB Vaccine Promises Hope Against Deadly Disease

A new generation HSP Subunit Vaccine, designed to combat Mycobacterium tuberculosis, is approaching commercial availability. Developed through collaborative research between the Indian Institute of Technology (IIT) Bhubaneswar and the Institute of Life Sciences (ILS) Bhubaneswar, this vaccine addresses the critical gap in preventing pulmonary tuberculosis in adolescents and adults.

The existing Bacillus Calmette Guérin (BCG) vaccine, over a century old, provides only limited protection to infants and is largely ineffective in older age groups. Tuberculosis remains a significant global health threat, with the WHO reporting 1.23 million deaths in 2024 alone, underscoring the urgent need for improved prevention strategies.

TechInvention Lifecare Limited has entered into a license agreement for the technology transfer and commercialization of this novel vaccine. This partnership aims to efficiently translate the indigenous vaccine technology from research to product development and eventual market availability, marking a significant step forward in India's efforts to control the TB epidemic.

trending

Grateful Dead's Bob Weir dies

trending

NFL playoff bracket updated

trending

Lightning beat Flyers 7-2

trending

NFL playoffs wild card weekend

trending

Yeison Jiménez plane accident

trending

Pacers beat Miami Heat

trending

Bears stun Green Bay Packers

trending

Hornets rout Jazz 150-95

trending

Sabres beat Ducks, win streak

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The new HSP Subunit Vaccine was jointly developed by IIT Bhubaneswar and the Institute of Life Sciences (ILS) Bhubaneswar.
The BCG vaccine is over a century old, offers limited protection to infants, and is largely ineffective against pulmonary TB in adolescents and adults.
The HSP Subunit Vaccine is expected to be commercially available soon following a licensing agreement.

Read more news on

Healthside-arrow

You may also like

HPV Vaccine Schedule Cut: Independent Review Launched

8 Jan • 17 reads

article image

UK Kids Unvaccinated: 1 in 5 Miss Deadly Disease Protection

1 Jan • 58 reads

article image

Indian Rabies Vaccine Linked to Counterfeit Scare

27 Dec, 2025 • 100 reads

article image

Hope for Nipah Virus: Vaccine Trials Begin in Bangladesh

9 Dec, 2025 • 205 reads

article image

mRNA Flu Shot Beats Standard Vaccine

20 Nov, 2025 • 132 reads

article image